M&A Deal Summary |
|
|---|---|
| Date | 2007-06-28 |
| Target | CellCarta |
| Sector | Life Science |
| Buyer(s) | Great Point Partners |
| Sellers(s) | Thallion Pharmaceuticals |
| Deal Type | Divestiture |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 2003 |
| PE ASSETS | 1.7B USD |
| Size | Large |
| Type | Sector Focused |
Great Point Partners is a private investment firm focused on investing in private and public healthcare companies. Great Point's private equity practice invests $10 to $100 million of growth capital in private, growing companies. Specific areas of interest within the healthcare sector includes biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and worker compensation companies. Great Point Partners was formed in 2003 and is based in Greenwich, Connecticut.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 36 |
| Sector: Life Science M&A | 2 of 14 |
| Type: Divestiture M&A Deals | 1 of 2 |
| State: Quebec M&A | 1 of 1 |
| Country: Canada M&A | 1 of 2 |
| Year: 2007 M&A | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-01-01 |
Biodel
Danbury, Connecticut, United States Biodel, Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-10-04 |
APT
Burlingame, California, United States APT is a specialty pharmaceuticals business focusing on rare lung diseases. APT is developing Pulminiq, a proprietary formulation of inhaled cyclosporine, for prevention of chronic rejection and death in lung transplant patients. Pulminiq is entering a pivotal Phase 3 trial in approximately 150 patients at leading lung transplant centers worldwide. APT was formed in 1999 and is based in Burlingame, California. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 2007 |
| Sector | Medical Products |
Thallion Pharmaceuticals Inc. (TSX: TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Quebec M&A | 1 of 1 |
| Country: Canada M&A | 1 of 1 |
| Year: 2007 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-03-14 |
CellCarta
Montreal, Quebec, Canada CellCarta is a provider of specialized precision medicine laboratory services to the biopharmaceutical industry. Leveraging its integrated analytical platforms in immunology, histopathology, proteomics and genomics, as well as related specimen collection and logistics services, CellCarta supports the entire drug development cycle, from discovery to late-stage clinical trials. CellCarta was founded in 2000 and is based in Montreal, Quebec. |
Buy | - |
